183 related articles for article (PubMed ID: 33353828)
1. Prognostic value of tumor regression grade following the administration of neoadjuvant chemotherapy as treatment for gastric/gastroesophageal adenocarcinoma: A meta-analysis of 14 published studies.
Hayashi M; Fujita T; Matsushita H
Eur J Surg Oncol; 2021 Aug; 47(8):1996-2003. PubMed ID: 33353828
[TBL] [Abstract][Full Text] [Related]
2. Comparison of five tumor regression grading systems for gastric adenocarcinoma after neoadjuvant chemotherapy: a retrospective study of 192 cases from National Cancer Center in China.
Zhu Y; Sun Y; Hu S; Jiang Y; Yue J; Xue X; Yang L; Xue L
BMC Gastroenterol; 2017 Mar; 17(1):41. PubMed ID: 28292272
[TBL] [Abstract][Full Text] [Related]
3. Prognostic and predictive value of mismatch repair deficiency in gastric and gastroesophageal junction adenocarcinoma patients receiving neoadjuvant or adjuvant chemotherapy.
Li Z; Wang Y; Ying X; Zhang L; Gao X; Jia Y; Zhang L; Wu A; Su X; Ji J
J Surg Oncol; 2021 Dec; 124(8):1356-1364. PubMed ID: 34515995
[TBL] [Abstract][Full Text] [Related]
4. Is pathologic tumor regression grade after neo-adjuvant chemotherapy a promising prognostic indicator for patients with locally advanced gastric cancer? A cohort study evaluating tumor regression response.
Xu X; Zheng G; Zhang T; Zhao Y; Zheng Z
Cancer Chemother Pharmacol; 2019 Sep; 84(3):635-646. PubMed ID: 31230156
[TBL] [Abstract][Full Text] [Related]
5. The effect of perioperative chemotherapy for patients with an adenocarcinoma of the gastroesophageal junction: A propensity score matched analysis.
Parry K; van Rossum PS; Haj Mohammad N; Ruurda JP; van Hillegersberg R
Eur J Surg Oncol; 2017 Jan; 43(1):226-233. PubMed ID: 27424786
[TBL] [Abstract][Full Text] [Related]
6. Tumor regression grade combined with post-therapy lymph node status: A novel independent prognostic factor for patients treated with neoadjuvant therapy followed by surgery in locally advanced gastroesophageal junction and gastric carcinoma.
Yin H; Yao Q; Xie Y; Niu D; Jiang W; Cao H; Feng X; Li Y; Li Y; Zhang X; Shen L; Chen Y
Cancer Med; 2023 Oct; 12(19):19633-19643. PubMed ID: 37749981
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the prognostic impact of pathologic response to preoperative chemotherapy using Mandard's Tumor Regression Grade (TRG) in gastric adenocarcinoma.
Derieux S; Svrcek M; Manela S; Lagorce-Pages C; Berger A; André T; Taieb J; Paye F; Voron T
Dig Liver Dis; 2020 Jan; 52(1):107-114. PubMed ID: 31427088
[TBL] [Abstract][Full Text] [Related]
8. Preferred neoadjuvant therapy for gastric and gastroesophageal junction adenocarcinoma: a systematic review and network meta-analysis.
Grizzi G; Petrelli F; Di Bartolomeo M; Viti M; Texeira Moraes M; Luciani A; Passalacqua R; Ghidini M; Tomasello G; Baiocchi GL; Celotti A
Gastric Cancer; 2022 Sep; 25(5):982-987. PubMed ID: 35704113
[TBL] [Abstract][Full Text] [Related]
9. NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors.
Schulz C; Kullmann F; Kunzmann V; Fuchs M; Geissler M; Vehling-Kaiser U; Stauder H; Wein A; Al-Batran SE; Kubin T; Schäfer C; Stintzing S; Giessen C; Modest DP; Ridwelski K; Heinemann V
Int J Cancer; 2015 Aug; 137(3):678-85. PubMed ID: 25530271
[TBL] [Abstract][Full Text] [Related]
10. The optimal neoadjuvant chemotherapy regimen for locally advanced gastric and gastroesophageal junction adenocarcinoma: a systematic review and Bayesian network meta-analysis.
Wang T; Li C; Li X; Zhai J; Wang S; Shen L
Eur J Med Res; 2022 Nov; 27(1):239. PubMed ID: 36352476
[TBL] [Abstract][Full Text] [Related]
11. Tumor regression grading after neoadjuvant treatment of esophageal and gastroesophageal junction adenocarcinoma: results of an international Delphi consensus survey.
Saliba G; Detlefsen S; Carneiro F; Conner J; Dorer R; Fléjou JF; Hahn H; Kamaradova K; Mastracci L; Meijer SL; Sabo E; Sheahan K; Riddell R; Wang N; Yantiss RK; Lundell L; Low D; Vieth M; Klevebro F
Hum Pathol; 2021 Feb; 108():60-67. PubMed ID: 33221343
[TBL] [Abstract][Full Text] [Related]
12. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial].
Tian Y; Wang Q; Wang J; Qiao XY; Zhang J; Lin YC; Li Y; Fan LQ; Yang PG; Zhao Q
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):128-137. PubMed ID: 33508918
[No Abstract] [Full Text] [Related]
13. Prognostic value of pathological tumor regression grade in locally advanced gastric cancer: New perspectives from a single-center experience.
Lombardi PM; Mazzola M; Achilli P; Aquilano MC; De Martini P; Curaba A; Gualtierotti M; Bertoglio CL; Magistro C; Ferrari G
J Surg Oncol; 2021 Mar; 123(4):923-931. PubMed ID: 33497471
[TBL] [Abstract][Full Text] [Related]
14. Tumour regression grade (TRG) analyses in patients with resectable gastro-oesophageal adenocarcinomas treated with platinum-based neoadjuvant chemotherapy.
Fareed KR; Ilyas M; Kaye PV; Soomro IN; Lobo DN; Parsons SL; Madhusudan S
Histopathology; 2009 Oct; 55(4):399-406. PubMed ID: 19817890
[TBL] [Abstract][Full Text] [Related]
15. Nodal downstaging to ypN0 after neoadjuvant chemotherapy positively impacts on survival of cT4N+ GC/GEJ patients.
Wu L; Xing Z; Huang M; Yu H; Qin Y; Jin Q; Zhou Z; Chen J
J Surg Oncol; 2022 Dec; 126(8):1403-1412. PubMed ID: 36001384
[TBL] [Abstract][Full Text] [Related]
16. Preoperative docetaxel/cisplatin/5-fluorouracil chemotherapy in patients with locally advanced gastro-esophageal adenocarcinoma.
Bayraktar UD; Bayraktar S; Hosein P; Chen E; Koniaris LG; Rocha-Lima CM; Montero AJ
Med Oncol; 2012 Sep; 29(3):1707-10. PubMed ID: 22033912
[TBL] [Abstract][Full Text] [Related]
17. Post-therapeutic response evaluation by a combination of endoscopy and CT scan in esophagogastric adenocarcinoma after chemotherapy: better than its reputation.
Blank S; Lordick F; Bader F; Burian M; Dobritz M; Grenacher L; Becker K; Weichert W; Langer R; Sisic L; Stange A; Jäger D; Büchler M; Bruckner T; Siewert J; Ott K
Gastric Cancer; 2015 Apr; 18(2):314-25. PubMed ID: 24722800
[TBL] [Abstract][Full Text] [Related]
18. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
[TBL] [Abstract][Full Text] [Related]
19. RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction - a randomized phase III joint study of the AIO, ARO and DGAV.
Lorenzen S; Biederstädt A; Ronellenfitsch U; Reißfelder C; Mönig S; Wenz F; Pauligk C; Walker M; Al-Batran SE; Haller B; Hofheinz RD
BMC Cancer; 2020 Sep; 20(1):886. PubMed ID: 32933498
[TBL] [Abstract][Full Text] [Related]
20. Dynamic changes in systemic immune-inflammation index predict pathological tumor response and overall survival in patients with gastric or gastroesophageal junction cancer receiving neoadjuvant chemotherapy.
Demircan NC; Atcı MM; Demir M; Işık S; Akagündüz B
Asia Pac J Clin Oncol; 2023 Feb; 19(1):104-112. PubMed ID: 35538045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
